Drug Developed for Inherited Bleeding Disorder Shows Promising Trial Results
A study led by Mass General Brigham researchers found that engasertib lessened bleeding events for patients with HHT, the second most common inherited bleeding disorder.
Press Release5 Minute ReadAug | 19 | 2021
Mohammad S. Jalali, PhD, MScLagged reporting has clouded the understanding of the effects of the COVID-19 pandemic on opioid-related overdose deaths. Our work represents the first multi-state report with detailed analyses.
BOSTON – The COVID-19 pandemic has disrupted the social support and economic stability of many individuals, which experts have warned could lead to a rise in opioid overdoses and opioid-related deaths. In a recent study shared on medRxiv, researchers at Massachusetts General Hospital (MGH) and Harvard Medical School characterized how the nature of such deaths have changed in nine9 U.S. states since the onset of the pandemic.
The study examined trends in opioid overdose deaths in Alaska, Colorado, Connecticut, Indiana, Massachusetts, North Carolina, Rhode Island, Utah and Wyoming during the COVID-19 pandemic as compared with 2018 and 2019.
The analysis revealed various trends that arose during the pandemic:
“Drug overdose data are collected and reported more slowly than COVID-19 data, from about 4 to 8 months’ lag in Massachusetts and North Carolina to over one year in Maryland and Ohio,” says senior author Mohammad S. Jalali, PhD, MSc, a senior scientist at MGH’s Institute for Technology Assessment and an assistant professor at Harvard Medical School. “This lagged reporting has clouded the understanding of the effects of the COVID-19 pandemic on opioid-related overdose deaths. Our work represents the first multi-state report with detailed analyses.”
The results may be useful for identifying and treating at-risk individuals. “Practitioners and policy makers can use our findings to help them anticipate which groups of people might be most affected by opioid overdose and which types of policy interventions might be most effective given each state’s unique situation,” says lead author Gian-Gabriel P. Garcia, PhD, who was a postdoctoral fellow at MGH and Harvard Medical School during the study and is currently an assistant professor at Georgia Tech.
Co-authors of the study include Erin J. Stringfellow, PhD, MSW, Catherine DiGennaro, BA1, Nicole Poellinger, MPH, Jaden Wood, BA, and Sarah Wakeman, MD.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals."
A study led by Mass General Brigham researchers found that engasertib lessened bleeding events for patients with HHT, the second most common inherited bleeding disorder.
The Sean M. Healey & AMG Center for ALS at Mass General Brigham has selected Tiziana Life Sciences as one of the companies to enter the Healey ALS MyMatch Program. Learn more.
Mass General Brigham study of more than 11,000 adolescents and young adults found those who took buprenorphine for 12 months had almost half the risk of overdose compared to those who discontinued early.
In a study of nearly 30,000 female nurses under age 50, Mass General Brigham researchers found that a high intake of ultra-processed foods was associated with increased risk of adenomas, colon polyps which can be precursors of colorectal cancer.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital has contracted with Inflammasome Therapeutics to design a new Healey ALS MyMatch trial. Learn more.
Children born to mothers who had COVID-19 while pregnant face an elevated risk of developmental disorders by the time they turn 3 years old, including speech delays, autism, motor disorders, and other developmental delays, according to new research by investigators at Mass General Brigham.
